- Home
- CIK vs PLX Comparison
CIK vs PLX Comparison
Compare CIK & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIK
- PLX
- Stock Information
- Founded
- CIK 1987
- PLX 1993
- Country
- CIK United States
- PLX United States
- Employees
- CIK N/A
- PLX N/A
- Industry
- CIK Finance/Investors Services
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CIK Finance
- PLX Health Care
- Exchange
- CIK Nasdaq
- PLX Nasdaq
- Market Cap
- CIK 163.1M
- PLX 164.2M
- IPO Year
- CIK N/A
- PLX 1998
- Fundamental
- Price
- CIK $2.96
- PLX $2.60
- Analyst Decision
- CIK
- PLX Strong Buy
- Analyst Count
- CIK 0
- PLX 1
- Target Price
- CIK N/A
- PLX $15.00
- AVG Volume (30 Days)
- CIK 115.4K
- PLX 792.6K
- Earning Date
- CIK 01-01-0001
- PLX 11-13-2025
- Dividend Yield
- CIK 9.03%
- PLX N/A
- EPS Growth
- CIK N/A
- PLX N/A
- EPS
- CIK N/A
- PLX 0.08
- Revenue
- CIK N/A
- PLX $61,948,000.00
- Revenue This Year
- CIK N/A
- PLX $14.53
- Revenue Next Year
- CIK N/A
- PLX $75.77
- P/E Ratio
- CIK N/A
- PLX $33.57
- Revenue Growth
- CIK N/A
- PLX 62.79
- 52 Week Low
- CIK $2.50
- PLX $0.99
- 52 Week High
- CIK $3.19
- PLX $3.10
- Technical
- Relative Strength Index (RSI)
- CIK 48.51
- PLX 82.14
- Support Level
- CIK $2.96
- PLX $1.52
- Resistance Level
- CIK $3.00
- PLX $2.12
- Average True Range (ATR)
- CIK 0.03
- PLX 0.12
- MACD
- CIK -0.00
- PLX 0.05
- Stochastic Oscillator
- CIK 47.50
- PLX 96.79
About CIK Credit Suisse Asset Management Income Fund Inc.
Credit Suisse Asset Mgmt Income Fund Inc is a closed-end management investment company. The investment objective of the fund is to provide current income consistent with the preservation of capital. Credit Suisse serves as an investment adviser for the fund. Asset Management offers a wide range of investment products and functions across asset classes and investment styles. The division manages various regional portfolios, mutual funds, and other investment vehicles for governments, institutions, corporations and individuals.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.